NCT03903562 2026-04-06
V503-024
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
5 trialsNCT06491446 2026-02-18
Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts
Antiva Biosciences
Phase 1/2 Active not recruiting
NCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07281599 2026-02-02
EQUIP
Qurasense
Phase NA Recruiting
NCT06632912 2026-01-23
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
National Vaccine and Serum Institute, China
Phase 3 Active not recruiting